Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-seq data of NKX6-3 knockdown in the BCP-ALL cell line RCH-ACV

ABSTRACT: RNA-seq data of NKX6-3 knockdown in the BCP-ALL cell line RCH-ACV

PROVIDER: PRJEB92217 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Transcriptomic analysis of RCH-ACV cells whose SETDB2 was knocked down by shRNA

Project description:RCH-ACV cells was depleted for SETDB2 by shRNA lentivirus construct co-expressing mCherry fluorescent. After sorting of mCherry positive cells, the cells were cultured and expanded and total RNA was extracted for Microarray experiment.

2019-01-19 | GSE125329 | GEO

Epigenetic analysis of BlaER1 transdifferentiation

Project description:Study of BLaER1 cell line epigenetic changes induced throughout transdifferentiation. The Illumina Infinium MethylationEPIC Beadchip was used to obtain genomewide methylation profiles of BLaER1 cells at 7 different times throughout transdifferentiation treatment (0h, 3h, 12h, 24h, 48h, 72h and 168h). As a reference, the parental RCH-ACV cell line at 168h of treatment and anonymous donor blood derived macrophages were also profiled.

2019-11-28 | GSE132845 | GEO

FOXO1 knockdown is toxic for BCP-ALL cell lines

Project description:We found that FOXO1 knock-down inhibits cell cycle progression and induces apoptosis in BCP-ALL cell lines RS4;11 and 018Z.

2017-08-01 | GSE86066 | GEO

NSD2 E1099K drives relapse in pediatric acute lymphoblastic leukemia by disrupting 3D chromatin organization

Project description:The NSD2 p.E1099K (EK) mutation has been shown to be enriched in patients with relapsed ALL indicating a role in clonal evolution and drug resistance. We previously demonstrated that the impact of EK is highly cell context dependent. To uncover 3D chromatin architecture-related mechanisms underlying drug resistance, we performed Hi-C on three B-ALL cell lines heterozygous for NSD2 EK (RS4;11, RCH-ACV, SEM) and assessed changes upon knockdown.

2023-01-13 | GSE199754 | GEO

Expression data for childhood BCP-ALL xenografts

Project description:Primary xenografts were made from a variety of different high-risk childhood BCP-ALL leukemia samples.

2015-03-05 | GSE58290 | GEO

Transcriptomic analysis of RCH-ACV cells whose SETDB2 was knocked down by shRNA

Project description:Transcriptomic analysis of RCH-ACV cells whose SETDB2 was knocked down by shRNA

| PRJNA515882 | ENA

U01 UCSD MRSA Vancomycin Treatment BCP Data

Project description:Upload of all BCP data from vancomycin treated strains of Staphylococcus aureus.

2018-08-08 | MSV000082801 | MassIVE

Pseudobutyrivibrio sp. ACV-2

Project description:Pseudobutyrivibrio sp. ACV-2 Genome sequencing

| PRJNA254888 | ENA

The NSD2 p.E1099K Mutation is Enriched at Relapse and Confers Drug Resistance in a Cell Context Dependent Manner in Pediatric Acute Lymphoblastic Leukemia (RNA-Seq)

Project description:The NSD2 p.E1099K (EK) mutation increases methyltransferase activity and is observed in 10% of acute lymphoblastic leukemia (ALL) samples with enrichment at relapse indicating a role in clonal evolution and drug resistance. To discover mechanisms that mediate the clonal expansion, we engineered B-ALL cell lines (Reh, 697) to overexpress wildtype (WT) and EK NSD2, but observed no differences in proliferation, clonal growth, or chemosensitivity. To address whether NSD2 EK acts collaboratively with other pathways, we used shRNAs to knockdown expression of NSD2 in B-ALL cell lines heterozygous for NSD2 EK (RS4;11, RCH-ACV, SEM). Knockdown resulted in decreased proliferation in all three lines, decreased clonal growth in RCH-ACV, and increased sensitivity to chemotherapeutic agents routinely used in ALL therapy, although the pattern of drug sensitivity varied among cell lines implying that the oncogenic properties of NSD2 mutations are likely cell context specific and rely on cooperative pathways to exert its effect. Knockdown of both Type II and REIIBP EK isoforms had a greater impact than knockdown of Type II alone, suggesting that both SET containing EK isoforms contribute to phenotypic changes driving relapse. Furthermore, in vivo models using both cell lines and patient samples revealed dramatically enhanced proliferation of NSD2 EK compared to WT and reduced sensitivity to 6-mercaptopurine in the relapse sample relative to diagnosis. Finally, EK-mediated changes in chromatin state and transcriptional output differed dramatically among cell lines further supporting a cell context specific role of NSD2 EK. These results demonstrate a unique role of NSD2 EK in mediating clonal fitness through pleiotropic mechanisms dependent on the genetic and epigenetic landscape.

2020-04-23 | GSE149158 | GEO

The NSD2 p.E1099K Mutation is Enriched at Relapse and Confers Drug Resistance in a Cell Context Dependent Manner in Pediatric Acute Lymphoblastic Leukemia (ChIP-Seq)

2020-04-23 | GSE149157 | GEO